{
  "abstract": "Introduction: Damage specific DNA binding protein 2 (DDB2) is an UV-indiced DNA damage recognition factor and regulator of cancer development and progression. DDB2 has dual roles in several cancers, either as an oncogene or as a tumor suppressor gene, depending on cancer localization. Here, we investigated the unresolved role of DDB2 in pancreatic ductal adenocarcinoma (PDAC). Methods: The expression level of DDB2 in pancreatic cancer tissues and its correlation with patient survival were evaluated using publicly available data. Two PDAC cell models with CRISPR-modified DDB2 expression were developed: DDB2 was repressed in DDB2-high T3M4 cells (T3M4 DDB2-low) while DDB2 was overexpressed in DDB2-low Capan-2 cells (Capan-2 DDB2-high). Immunofluorescence and qPCR assays were used to investigate epithelial-to-mesenchymal transition (EMT) in these models. Migration and invasion properties of the cells were also determined using wound healing and transwell assays. Sensitivity to 5-fluorouracil (5-FU), oxaliplatin, irinotecan and gemcitabine were finally investigated by crystal violet assays. Results: DDB2 expression level was reduced in PDAC tissues compared to normal ones and DDB2-low levels were correlated to shorter disease-free survival in PDAC patients. DDB2 overexpression increased expression of E-cadherin epithelial marker, and decreased levels of N-cadherin mesenchymal marker. Conversely, we observed opposite effects in DDB2 repression and enhanced transcription of SNAIL, ZEB1, and TWIST EMT transcription factors (EMT-TFs). Study of migration and invasion revealed that these properties were negatively correlated with DDB2 expression in both cell models. DDB2 overexpression sensitized cells to 5-fluorouracil, oxaliplatin and gemcitabine. Conclusion: Our study highlights the potential tumor suppressive effects of DDB2 on PDAC progression. DDB2 could thus represent a promising therapeutic target or biomarker for defining prognosis and predicting chemotherapy response in patients with PDAC.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 14,
  "authors": [
    {
      "name": "Julie Dardare"
    },
    {
      "name": "Andréa Witz"
    },
    {
      "name": "Margaux Betz"
    },
    {
      "name": "Aurélie Francois"
    },
    {
      "name": "Morgane Meras"
    },
    {
      "name": "Laureline Lamy"
    },
    {
      "name": "Aurélien Lambert"
    },
    {
      "name": "Stéphanie Grandemange"
    },
    {
      "name": "Marie Husson"
    },
    {
      "name": "Marie Rouyer"
    },
    {
      "name": "Jessica Demange"
    },
    {
      "name": "Jean-Louis Merlin"
    },
    {
      "name": "Alexandre Harlé"
    },
    {
      "name": "Pauline Gilson"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/5ydz61madkf68.bib",
  "cited_by": 19,
  "doi": "10.3389/fonc.2022.1052163",
  "fulltext_url": null,
  "id": "5ydz61madkf68",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://hal.science/hal-03901664v1",
  "language": "en",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "hal",
      "1.sdv.bbm"
    ],
    [
      "hal",
      "1.sdv.can"
    ],
    [
      "hal",
      "1.sdv.mhep"
    ],
    [
      "hal",
      "2.sdv.bbm.gtp"
    ],
    [
      "hal",
      "2.sdv.mhep.heg"
    ],
    [
      "openalex",
      "2730|Pancreatic and Hepatic Oncology Research"
    ]
  ],
  "openalex": "W4311870290",
  "pdf_url": "https://hal.science/hal-03901664/document",
  "pmcid": null,
  "pmid": null,
  "published": "2026-09-02",
  "publisher": "Frontiers Media",
  "ris": "https://research.draconitic.com/paper/5ydz61madkf68.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:24Z",
      "native_id": "hal-03901664",
      "source": "hal",
      "url": "https://hal.science/hal-03901664v1"
    }
  ],
  "subjects": [
    {
      "field": "biochemistry",
      "origin": "hal:2.sdv.bbm.gtp",
      "subfield": "proteomics-metabolomics"
    },
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    },
    {
      "field": "medicine",
      "origin": "hal:1.sdv.can",
      "subfield": "oncology"
    }
  ],
  "title": "DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy",
  "title_text": "DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:24Z",
  "url": "https://research.draconitic.com/paper/5ydz61madkf68",
  "venue": "Frontiers in Oncology",
  "versions": []
}